Chemical Structure (Belsomra 01)
Belsomra Tablet, Film Coated
Product Images NDC 0006-0033
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Belsomra (NDC 0006-0033). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Merck Sharp & Dohme Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Belsomra 02)
This is a table showing the mean effect and 90% confidence interval of interacting drugs with a strong CYP3A inhibitor, moderate CYP3A inhibitor, and strong CYP3A inducer. The recommended starting and maximum doses are also listed. The chart shows the change relative to the reference for AUC.*
Figure 2 (Belsomra 03)
This text appears to be a table or chart displaying information about drug interactions and recommended dose adjustments for certain substrates such as CYP3A and CYP2C9. It includes specific drugs such as midazolam and warfarin, as well as information about combined oral contraceptives. Without proper formatting, the text is difficult to decipher and interpret.*
Principal Display Panel (5 mg Tablet Blister Card Case Carton)
Belsomra is a medication used in the treatment of insomnia. It comes in the form of tablets containing 5mg suvorexant. It is advised to refer to the medication guide provided with the product for proper usage. The tablets should be stored in their original packaging to maintain their effectiveness. The medication is manufactured by Merck & Co. Inc.*
Principal Display Panel (10 mg Tablet Blister Card Case Carton)
Belsomra is a medication available in tablet form containing 10mg suvorexant and packaged in 30 tablets per blister pack. It is used for treating insomnia in patients. The tablets should be stored at a temperature between 15° and 30°C and protected from light and moisture. Additional details about the medication may be obtained from the accompanying medication guide.*
Principal Display Panel (15 mg Tablet Blister Card Case Carton)
Belsomra is a medication administered in tablet form that contains 15 mg of suvorexant. It comes in a package of 10 tablets, and there is an accompanying prescription guide for patients. It is recommended that patients adhere to the dosage instructions provided in the package. The medication needs to be stored in its original packaging, protected from light, at room temperature, and should not be given to or shared with others. The text includes some illegible characters.*
Principal Display Panel (20 mg Tablet Blister Card Case Carton)
Belsomra (suvorexant) tablets are sold in a package containing 10 blister tablets. Each tablet contains 20mg suvorexant, and comes with a medication guide. The recommended dosage is stated on the package, and the tablets should be stored at room temperature. It is illegal to sell or give away this medication. Pharmacy label can be placed on the package.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
